ORIC Pharmaceuticals recently showcased promising preclinical findings for ORIC-944 at the 2025 American Association for Cancer Research annual meeting. ORIC-944 is an orally bioavailable, highly selective allosteric inhibitor of PRC2, demonstrating significant potential when used with androgen receptor pathway inhibitors (ARPIs) in prostate cancer treatment.
According to the data, ORIC-944 not only increased progression-free survival in both castration-sensitive and castration-resistant prostate cancer models but also exhibited synergistic and antitumor effects when combined with ARPIs. The compound has shown strong inhibition of PRC2 and promoted a stable luminal cell state by limiting access to lineage transcription factors, consequently enhancing chromatin remodeling.
The study suggests that ORIC-944 could be a leading PRC2 inhibitor capable of blocking tumor adaptation and restoring cancer cells' luminal features, thereby making them more susceptible to ARPI treatments. Currently, ORIC-944 is under investigation in combination with Erleada and Nubeqa in an ongoing Phase 1b trial aimed at improving prostate cancer outcomes.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for ORIC Pharmaceuticals Inc (ORIC, Financial) is $17.57 with a high estimate of $22.00 and a low estimate of $13.00. The average target implies an upside of 245.21% from the current price of $5.09. More detailed estimate data can be found on the ORIC Pharmaceuticals Inc (ORIC) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, ORIC Pharmaceuticals Inc's (ORIC, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
